Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman ...

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...

Boston Scientific (NYSE:BSX) announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Regulatory approvals and trials, particularly for WATCHMAN FLX Pro and FARAPULSE, are crucial for future performance and could introduce short-term volatility. Given the rich valuation and ...

(RTTNews) - Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure (LAAC) Device.

WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure ...